Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,906 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).
Kajiwara T, Nishina T, Yamashita R, Nakamura Y, Shiozawa M, Yuki S, Taniguchi H, Hara H, Ohta T, Esaki T, Shinozaki E, Takashima A, Yamamoto Y, Yamazaki K, Yoshino T, Hyodo I. Kajiwara T, et al. Among authors: taniguchi h. Cancers (Basel). 2023 Oct 27;15(21):5172. doi: 10.3390/cancers15215172. Cancers (Basel). 2023. PMID: 37958346 Free PMC article.
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Narita Y, Todaka A, Ishihara M, Yokota T, Tanaka T, Machida N, Kadowaki S, Fukutomi A, Ura T, Onozawa Y, Ando M, Tajika M, Muro K, Yasui H, Mori K, Taniguchi H. Hamauchi S, et al. Among authors: taniguchi h. Clin Colorectal Cancer. 2017 Mar;16(1):51-57. doi: 10.1016/j.clcc.2016.07.005. Epub 2016 Jul 21. Clin Colorectal Cancer. 2017. PMID: 27522626
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T, Taniguchi H, Hamauchi S, Komori A, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Masuishi T, et al. Among authors: taniguchi h. Clin Colorectal Cancer. 2017 Jun;16(2):e15-e22. doi: 10.1016/j.clcc.2016.07.019. Epub 2016 Aug 31. Clin Colorectal Cancer. 2017. PMID: 27670892
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.
Narita Y, Kadowaki S, Masuishi T, Taniguchi H, Takahari D, Ura T, Ando M, Tajika M, Niwa Y, Eto T, Hara H, Asayama M, Yamaguchi K, Yatabe Y, Muro K. Narita Y, et al. Among authors: taniguchi h. Oncol Lett. 2017 Aug;14(2):2545-2551. doi: 10.3892/ol.2017.6409. Epub 2017 Jun 19. Oncol Lett. 2017. PMID: 28781693 Free PMC article.
Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Komori A, Taniguchi H, Hamauchi S, Masuishi T, Kito Y, Narita Y, Tsushima T, Ishihara M, Todaka A, Tanaka T, Yokota T, Kadowaki S, Machida N, Ura T, Fukutomi A, Ando M, Onozawa Y, Tajika M, Yasui H, Muro K, Mori K, Yamazaki K. Komori A, et al. Among authors: taniguchi h. Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2. Oncology. 2017. PMID: 28866662
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y. Moriwaki T, et al. Among authors: taniguchi h. Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11. Oncologist. 2018. PMID: 28894015 Free PMC article.
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. Oki E, et al. Among authors: taniguchi h. Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9. Clin Colorectal Cancer. 2018. PMID: 29530335 Free article. Clinical Trial.
Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E. Tsuchihashi K, et al. Among authors: taniguchi h. Clin Colorectal Cancer. 2018 Dec;17(4):e687-e697. doi: 10.1016/j.clcc.2018.07.004. Epub 2018 Jul 29. Clin Colorectal Cancer. 2018. PMID: 30149986
2,906 results